News
Video
Author(s):
Data show excellent refractive stability, strong visual acuity across all distances, and contrast sensitivity comparable to monofocal IOLs.
Steven J. Dell, MD, of Dell Laser Consultants, Austin, Texas, presented the 24-month refractive stability and visual acuity data for the OmniVu accommodating IOL (Atia Vision) at the 2025 American Society of Cataract and Refractive Surgery annual meeting, held April 25 to 28, in Los Angeles, California. Reporting on 19 patients (29 eyes), Dell noted, “It was frankly some of the best data that I've ever seen on refractive predictability for any IOL of any type.”
The lens demonstrated excellent refractive stability over 24 months, with strong alignment between early postoperative, 1-year, and 2-year data. Patients achieved excellent uncorrected distance, intermediate, and near vision. Critically, for binocular vision at intermediate distance through the distance correction, mean acuity was 20/20, and for near, 20/25. “Very, very good data and very functional vision throughout the visual spectrum,” Dell emphasized.
The lens' unique dual-optic design — with a fluid-filled posterior optic responsive to ciliary muscle contraction and a fixed anterior optic — aims to deliver stable, predictable refractive outcomes. Its bag-filling approach helps maintain capsular clarity and mimics the size of the natural crystalline lens. “The quality of vision with this design is comparable to any monofocal IOL,” Dell said, highlighting minimal dysphotopsia and a continuous range of clear vision, long sought after in accommodating lens technology.
He was also pleased to report that “contrast sensitivity data was really comparable to what we see with monofocal IOLs,” and that both astigmatism and spherical equivalent remained stable across the 24-month follow-up.
“There are a number of accommodating IOL designs out there,” Dell concluded, “but I think it's fair to say that the Atia Vision OmniVu lens is the one that is furthest into the process.”
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.